Valuation dashboard for Ocugen, Inc. (OCGN) with P/E N/A, P/B -20.88, EV/EBITDA -6.40 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigme...
Analysis Summary
Ocugen, Inc. reported revenue of $4.4M in the most recent fiscal year, growing at a 5-year CAGR of 152.5%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -15.0%, net margin -17.9%.
At the current price of $1.00, OCGN has negative trailing earnings (P/E not meaningful) and an ROE of 16.88%. Market capitalisation stands at $339M.
Balance sheet quality for OCGN: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -20.88 |
| EV / EBITDA | -6.40 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.19 |
| vs Current Price | -119.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OCGN | Ocugen, Inc. | $339M | 16.9% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.00 |
| Market Cap | $339M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 1688.22% |
| Return on Invested Capital | -92.68% |
| Return on Assets | -65.87% |
| Gross Margin | 100.00% |
| Operating Margin | -1504.43% |
| Net Margin | -1786.27% |
Related companies: ADCT · ALMS · CMPX · FULC · LCTX · LXRX · NGNE
Explore sector: Healthcare · Biotechnology
More sections of OCGN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks